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used. Cartilage degradation was monitored by measuring the
conditioned medium in 4 independent assays (1) 342-G2 assay,
composed of the capturing antibody AF-28 against the 342FFGVG
neo-epitope generated by MMP-cleavage and the monoclonal
antibody F-78 binding to both the Globular 1 (G1) and Globu-
lar 2 (G2) domain of aggrecan; (2) 374-G2 assay, made up by
the capturing antibody BC-3 against the 374ARGSVI neo-epitope
created by ADAMTs cleavage and F-78; (3) MMP mediated colla-
gen type II degradation (CTX-II) quantified by ELISA; (4) release
of total glycosaminoglycans (GAGs). Furthermore, immunohisto-
chemistry was performed with the monoclonal antibodies AF-28
and BC-3 on OA cartilage to localize the epitopes.
Results: OSM/TNFα caused a significant release of aggre-
canase mediated 374-G2 containing molecules in the early (day
4-9), mid (day 10-15) and late phase (day 16-21) and GAGs in
the early and mid phase compared to non-stimulated explants
(1000 fold increase of 374-G2 at day 14). On the other hand,
stimulation with IL-1α resulted in a release of aggrecanase me-
diated 374-G2 antigens and GAGs in the mid and late phase
when compared to non-stimulated explants (50 fold increase of
374-G2 at day 14). No remarkable release of MMP mediated
CTX-II or 342-G2 analytes were detected with OSM/TNFα or IL-
1α throughout the whole period. Immunohistochemistry showed
an intense staining with BC-3 in the calcified cartilage zone and
in the articular surface, where erosion had occurred.
Conclusions: In the present study, we have shown that stim-
ulation of ex vivo human explant cultures with OSM/TNFα or
IL-1α results in release of aggrecanase mediated 374-G2 an-
alytes, but not MMP mediated 342-G2 molecules. By careful
assessment of biochemical markers, these provide information
on which proteases are activated, when stimulating explants with
pro-inflammatory cytokines. We suggest that these assays are
valuable diagnostic tools for assessing the turnover of aggre-
can in human arthritis, which may aid in understanding disease
mechanisms leading to pathologies such as OA.
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Purpose: Osteoarthritis (OA) is usually used as a control for
rheumatoid arthritis (RA) when measuring innate and specific re-
ceptor levels. However, there is evidence that there is a systemic
inflammatory component to OA as well. In the current study, we
examined CD14+ peripheral blood monocytes from OA patients
for the expression of Toll-like receptors (TLR), TLR2 and TLR4,
and co-stimulatory molecules, CD80 and CD86, in order to de-
termine whether the cells from OA patients have increased levels
compared with normals. Monocytes from RA patients were also
compared.
Methods: Blood was collected 45 patients with OA, 45 patients
with RA, and 25 normals. TLR2 and TLR4 expression on CD14+
peripheral blood mononuclear cells (PBMCs) were measured by
flow cytometry using anti-CD14, anti-TLR2 and anti-TLR4 mono-
clonal antibodies. CD80 and CD86 expression on CD14+PBMCs
were also measured by flow cytometry using anti-CD14, anti-
CD80 and anti-CD86 monoclonal antibodies. Appropriate isotype
controls were used. Results are expressed as a ratio to control.
Results: Preliminary data suggest TLR2 expression (expressed
as a ratio to control) was significantly increased for OA patients
(p<0.05) and RA patients (p<0.05), compared with normals. For
OA monocytes, TLR4 expression (expressed as a ratio to control)
was no different to normals, whereas expression was decreased
on cells from RA patients (p<0.05). CD14highCD16+ monocytes
showed the greatest expression of TLR2 on both OA and RA
monocytes. The co-stimulatory molecules CD80 and CD86 were
not increased on OA monocytes, whereas CD86 was increased
on RA monocytes.
Conclusions: OA monocytes show some differences from nor-
mal monocytes, at least in TLR2 expression, suggesting perhaps
that aspects of the innate immune system may be involved in OA
pathogenesis.
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Purpose: To evaluate the sensitivity of a panel of biomarkers for
type II collagen turnover, alone or in combination, to differentiate
patients with radiographic and symptomatic osteoarthritis (OA)
from healthy controls that could be used to help monitor OA
disease progression and therapeutic intervention.
Methods: Levels of the urinary type II collagen degradation
biomarkers uCTX-II and uTIINE, and the blood type II collagen
synthesis biomarkers plNPII, sCPII and sPIIANP were measured
in 177 subjects aged > 40 years (mean = 57). Eighty-four
patients had symptomatic OA in at least one knee. The diagnosis
of symptomatic OA (SOA) was based on a combination of pain
or stiffness on most days of a month during the past year and
the presence of radiographic OA as defined by Kellgren and
Lawrence grades (KLG) 2 and 3. Ninety-three age- and sex-
matched healthy controls had no symptoms and a KLG = 0.
ELISA assays were used to measure uCTX-II, sPIIANP (Synarc,
France) and sCPII (IBEX, Canada). uTIINE was measured by
LC/MS/MS and plNPII was measured by a recently developed
competitive ELISA assay in-house. Statistical analyses were
performed on Log-transformed data.
Results: The mean (SD) levels of uCTXII, uTIINE, plNPII, sCPII
and sPIIANP, were 203.39 (119.8) ng/mmol Creat, 76.95 (48.89)
ng/mmol Creat, 3.48 (3.65) ng/mL, 402.43 (126.83) ng/mL and
902.97 (669.55) ng/mL, respectively. The uCTXII and uTIINE
levels were significantly larger in OA patients compared to control
subjects (P-value <0.001). In contrast, the plNPII levels were
significantly smaller in OA patients compared to control subjects
(P-value = 0.04). Both sCPII and sPIIANP levels were similar
in both groups (P-value = 0.52 and 0.27, respectively). Levels
of both degradation markers uCTX-II and uTIINE were well
correlated (R = 0.64, p < 0.0001). Among the synthesis markers,
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sCPII and sPIIANP only appeared to be correlated (R = 0.29;
p = 0.002). Between synthesis and degradation markers, only
sCPII and uCTX-II appeared to be weakly correlated (R = 0.18;
p = 0.016). The ratio of uCTX-II or uTIINE to sCPII enhanced the
differences between OA patients and control subjects.
Conclusions: In the present study, the combination of both syn-
thesis and degradation markers of type II collagen appeared to
better differentiate OA patients from healthy volunteers. However,
each of these markers may reflect the activity of different set of
enzymes that may play a critical role at different stages of the
disease, and therefore evaluation of the full panel of biomarkers
may be required to understand disease progression and potential
therapies.
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Purpose: In classic collagen-induced arthritis (CIA) models, the
disease is induced by injection of type II collagen. Such murine
CIA models are widely used to study the pathology of rheumatoid
arthritis (RA) and to evaluate the effects of potential anti-arthitic
drugs. Recently, a rapid murine model of RA employing mono-
clonal antibodies against type II collagen was developed which
reduces the timeline compared to classic CIA experiments.
The objective of the present study was to characterize the clinical,
biochemical, 3-D microstructural and histopathological features
in BALB/c mice injected with anti-type II collagen antibodies.
Methods: 48 eight-week-old mice were randomly assigned to
6 groups with 8 mice in each group: One control group (non-
diseased), four CIA groups and one CIA + dexamethasone
(Dex) group. CIA was induced by intravenous injection of 2 or 4
mg/mouse Arthrogen-CIA® anti-type II collagen antibodies (mAB)
on day 1 followed by 25 or 50 μg/mouse lipopolysaccharide (LPS)
on day 3. Additionally, the treated group induced with 2 mg mAB
and 50 μg LPS received daily doses of Dex (0.5 mg/kg) by
gavage following onset of the disease (day 5) until termination of
the experiment (day 15).
Paw inflammation (redness and swelling) were evaluated daily
for all animals.
Circulating levels of matrix metalloproteinase-derived fragments
of collagen type II were measured at study termination by serum
CTX-II. Structural changes were evaluated by histopathology and
micro-CT scanning of the hindpaws.
Results: On the 5th day after induction of disease all CIA mice
had significantly higher paw inflammation scores than the control
group (p<0.05). Hereafter the treated group received daily doses
of Dex, and at study termination the paw inflammation score for
this group had decreased to the level of the control group and
was significantly different from the CIA group (p<0.05).
The levels of MMP-derived collagen type II fragments in serum at
study termination were found to correlate to the paw inflammation
scores (p<0.001). As shown in Figure 1, the serum levels of
collagen type II fragments for the CIA group induced by 2
mg mAB and 50 μg LPS (B) were significantly increased at
termination compared to the non-diseased control group (A)
(p=0.027). Daily doses of Dex were able to suppress the level of
these fragments in the treated group (C) compared to the CIA
group (B) (p<0.0001).
Histopathology demonstrated a noticeable reduction in inflamma-
tion, cartilage damage, bone resorption and osteophyte formation
in the group treated with Dex compared to the CIA groups.
Micro-CT analyses of the hindpaws showed a marked increase
in the extent of new bone formation and a slight increase in
bone resorption in the CIA groups compared to the non-diseased
control group and demonstrated the complete prevention of these
changes in the treated group.
Fig. 1. Levels of MMP-derived fragments of collagen type II in serum at study
termination. A) Non-diseased control group. B) CIA group. C) CIA + dexametha-
sone group.
Conclusions: Intravenous injection of 2 mg mAB followed by
50 μg of LPS induced a persistent disease in the BALB/c mice
with an incidence of 100%. Moreover, treatment with 0.5 mg/kg
dexamethasone relieved the mice from all of the assessed dis-
ease parameters. The anti-inflammatory action of dexametha-
sone was reflected in a dramatic decrease in serum levels of
matrix metalloproteinase-derived fragments of collagen type II.
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Purpose: The Osteoarthritis Initiative (OAI) is targeted at iden-
tifying biomarkers for development and progression of symp-
tomatic knee OA. Magnetic resonance (MR) imaging can pro-
vide three-dimensional metrics of cartilage morphology, with fast
low angle shot (FLASH) and double echo steady state (DESS)
sequences with water excitation having been validated in this
context at 3 Tesla. The purpose of this pilot is to compare the
sensitivity of the two sequences to detect change in cartilage
volume over 2 years.
Methods: 9 participants with mild to moderate OA were exam-
ined twice at baseline (BL), twice at 1 year (Y1), and once at
2 years (Y2). A double oblique coronal FLASH with 1.5 mm
slice thickness and a sagittal DESS with 0.7 mm slice thickness
were acquired. Coronal multiplanar reformats (MPR) from the
DESS were obtained at 1.5 mm slice thickness. Femorotibial
joint cartilage plates (medial and lateral tibia = MT/LT, central
medial/lateral central femoral condyles = cMF/cLF) were exam-
ined using FLASH, DESS and MPR, and the patella (P) and
posterior medial and lateral femoral condyles (pMF/pLF) with
the sagittal DESS. Proprietary software (Chondrometrics GmbH,
Ainring, Germany) was used for image analysis. Knees were
analyzed in quadruples (Y1) and pairs (Y2) with blinding to the
order of acquisition. In the femorotibial compartment, aggregate
